Stock Events

Stock Events

Aptose Biosciences 

$1.6900
76
+$0.00+0% Thursday 20:00

Statistics

Day High
1.72
Day Low
1.69
52W High
1.85
52W Low
1.01
Volume
426
Avg. Volume
2,158
Mkt Cap
4.31M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

4AugExpected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-17.91
-12.5
-7.09
-1.68
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-7.04MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow APTOF. It's not an investment recommendation.
BCE
6
BCE.TO
Canadian Imperial Bank Of Commerce
6
CM.TO
Microsoft
5
MSFT
Enbridge
5
ENB.TO

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Agios Pharmaceuticals
AGIO
Mkt Cap2.22B
Agios Pharmaceuticals focuses on cellular metabolism and rare genetic diseases, directly competing in the oncology and hematology space similar to Aptose's focus.
Incyte
INCY
Mkt Cap23.32B
Incyte Corporation specializes in oncology products, directly competing with Aptose in developing treatments for hematologic cancers.
TG Therapeutics
TGTX
Mkt Cap8.74B
TG Therapeutics focuses on developing treatments for B-cell malignancies and autoimmune diseases, overlapping with Aptose's research in hematologic malignancies.
Gilead Sciences
GILD
Mkt Cap161.19B
Gilead Sciences is a large biopharmaceutical company with a strong presence in oncology and hematology, making it a direct competitor.
Novartis
NVS
Mkt Cap293.94B
Novartis AG, with its extensive portfolio in healthcare, including treatments for cancer, competes in the same market as Aptose, especially in oncology.
AMGEN
AMGN
Mkt Cap196.12B
Amgen focuses on human therapeutics, including oncology/hematology, which puts it in direct competition with Aptose's cancer research efforts.
Karyopharm Therapeutics
KPTI
Mkt Cap218.02M
Karyopharm Therapeutics is involved in the discovery and development of drugs for the treatment of cancer, including hematologic malignancies, similar to Aptose's focus.
Abbvie
ABBV
Mkt Cap438.31B
AbbVie has a strong portfolio in oncology, including treatments for hematologic cancers, making it a competitor in the same therapeutic area as Aptose.

About

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes. It has license agreements with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
Show more...
CEO
Dr. William G. Rice Ph.D.
Country
Canada
ISIN
CA03835T4081

Listings

F
DE
LTI0.F
STU
DE
LTI0.STU
STU
DE
LTIA.STU
US
APTOF

0 Comments

Share your thoughts

FAQ

What is Aptose Biosciences stock price today?▼
The current price of APTOF is $1.69 USD — it has increased by +0% in the past 24 hours. Watch Aptose Biosciences stock price performance more closely on the chart.
What is Aptose Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Aptose Biosciences stocks are traded under the ticker APTOF.
Is Aptose Biosciences stock price growing?▼
APTOF stock has risen by +0% compared to the previous week, the month change is a +8.33% rise, over the last year Aptose Biosciences has showed a -8.65% decrease.
What is Aptose Biosciences market cap?▼
Today Aptose Biosciences has the market capitalization of 4.31M
When is the next Aptose Biosciences earnings date?▼
Aptose Biosciences is going to release the next earnings report on August 04, 2026.
What were Aptose Biosciences earnings last quarter?▼
APTOF earnings for the last quarter are -2.99 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Aptose Biosciences revenue for the last year?▼
Aptose Biosciences revenue for the last year amounts to 0 USD.
What is Aptose Biosciences net income for the last year?▼
APTOF net income for the last year is -7.04M USD.
In which sector is Aptose Biosciences located?▼
Aptose Biosciences operates in the Health & Wellness sector.
When did Aptose Biosciences complete a stock split?▼
The last stock split for Aptose Biosciences was on October 06, 2014 with a ratio of 1:12.
Where is Aptose Biosciences headquartered?▼
Aptose Biosciences is headquartered in Toronto, Canada.